A 24-month extension of a one-year, multicenter, double-blinded double dummy, randomized study to evaluate the safety and efficacy of two doses of FTY720 combined with full-dose cyclosporine, USP [Modified] (Novartis Brand) and steroids versus mycophenolate mofetil combined with full-dose cyclosporine, USP [Modified] (Novartis Brand) and steroids, in adult de novo renal transplant recipients.

Trial Profile

A 24-month extension of a one-year, multicenter, double-blinded double dummy, randomized study to evaluate the safety and efficacy of two doses of FTY720 combined with full-dose cyclosporine, USP [Modified] (Novartis Brand) and steroids versus mycophenolate mofetil combined with full-dose cyclosporine, USP [Modified] (Novartis Brand) and steroids, in adult de novo renal transplant recipients.

Completed
Phase of Trial: Phase II

Latest Information Update: 01 Mar 2017

At a glance

  • Drugs Ciclosporin; Corticosteroids; Fingolimod; Mycophenolate mofetil
  • Indications Renal transplant rejection
  • Focus Therapeutic Use
  • Sponsors Novartis
  • Most Recent Events

    • 01 Nov 2011 Actual end date (November 2006) added as reported by ClinicalTrials.gov.
    • 24 Mar 2009 Primary outcomes added as reported by ClinicalTrials.gov.
    • 17 Dec 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top